EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

LIVERSTAT for risk stratification for patients with metabolic dysfunction‐associated fatty liver disease

Yong Wen Leow, Wah Loong Chan, Lee Lee Lai, Nik Raihan Nik Mustapha, Sanjiv Mahadeva iD, Ronald Quiambao, Mona Munteanu, Wah Kheong Chan iD

Journal of Gastroenterology and Hepatology · 2024

DOI: 10.1111/jgh.16675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Yong Wen Leow und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Elasticity Imaging Techniques, Biomarkers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fibronostics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim LIVERSTAT is an artificial intelligence‐based noninvasive test devised to screen for and provide risk stratification for metabolic dysfunction‐associated fatty liver disease (MAFLD) by using simple blood biomarkers and anthropometric measurements. We aimed to study LIVERSTAT in patients with MAFLD and to explore its role for the diagnosis of advanced fibrosis. Methods This is a retrospective study of data from MAFLD patients who underwent a liver biopsy. Patients with type 2 diabetes who underwent transient elastography and had liver stiffness measurement (LSM) < 5 kPa were included as patients with no fibrosis. Among these patients, controlled attenuation parameter

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Elasticity Imaging TechniquesBiomarkersHumansMaleMiddle AgedFemaleRetrospective StudiesRisk AssessmentLiver CirrhosisArtificial IntelligencePredictive Value of TestsDiabetes Mellitus, Type 2AdultFatty LiverLiverSensitivity and SpecificityBiopsyAgedNon-alcoholic Fatty Liver DiseaseAlgorithmsMetabolic Diseases

Stichwörter der Autor:innen

Fibrosis‐4 indexMAFLDMASLDfibrosismetabolic dysfunction‐associated steatotic liver disease

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Department of Pathology, Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia.
  • Medical Affairs, Fibronostics US Inc., Indian Harbour Beach, Florida, USA.

ORCID-Profile: Sanjiv Mahadeva, Wah Kheong Chan

Förderung

  • Fibronostics

Zitieren

APA

Leow, Y. W., Chan, W. L., Lai, L. L., Mustapha, N. R. N., Mahadeva, S., Quiambao, R., Munteanu, M., & Chan, W. K. (2024). LIVERSTAT for risk stratification for patients with metabolic dysfunction‐associated fatty liver disease. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16675

Vancouver

Leow YW, Chan WL, Lai LL, Mustapha NRN, Mahadeva S, Quiambao R, et al. LIVERSTAT for risk stratification for patients with metabolic dysfunction‐associated fatty liver disease. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16675

BibTeX
@article{Leow2024,
  author = {Leow, Yong Wen and Chan, Wah Loong and Lai, Lee Lee and Mustapha, Nik Raihan Nik and Mahadeva, Sanjiv and Quiambao, Ronald and Munteanu, Mona and Chan, Wah Kheong},
  title = {LIVERSTAT for risk stratification for patients with metabolic dysfunction‐associated fatty liver disease},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1111/jgh.16675}
}
Kostenlos starten →